Press releases

A live webcast and replay of the November 6 presentations will be available at Boston Scientific's website

Thousands of heart failure patients are now eligible for additional pacing feature

Zelenkofske to lead development and implementation of pre- and post-market clinical strategy that supports Company's CRM technology and therapy portfolio

Positive results also reported for TAXUS Liberte stent direct stenting

Results were announced at the Cardiovascular Research Foundation's (CRF) eighteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, in Washington, D.C.

Results also show statistically significant late stent thrombosis rate for Cypher® stent vs. bare-metal stent

Two-year results continue to evaluate long-term safety and efficacy

Multi-center registry to enroll 10,000 patients over two years

Study of 1,558 patients was designed to retrospectively compare one-year clinical outcomes in real-world practice

"In Q3 we were able to achieve results near the high end of our previously announced preliminary sales and earnings ranges," said Jim Tobin, President and CEO

Results to include new data on next-generation TAXUS® Liberte™ Stent System

MAPS trial demonstrates Company's commitment to understanding the efficacy and durability of endovascular therapies for the treatment of brain aneurysms

Boston Scientific Corporation (NYSE: BSX) announced today that the PROMUS™ Everolimus-Eluting Coronary Stent System has received CE Mark...

Victory supports previous court decisions related to the suit Medtronic filed against Guidant in August 2003

A live webcast and replay of the October 18 conference call will be available

FDA approval makes remote monitoring available by more than 150,000 additional patients

Gobierno de Puerto Rico aprueba el Sistema Precision, que brinda a los médicos una nueva opción de tratamiento para dolor agudo y crónico

Plans for changes consistent with HRS guidelines includes Company's commitment to the development of independent, industry-wide oversight to facilitate consistent communications, surveillance and product performance reporting practices

New cochlear implant technology to significantly increase hearing potential and quality of life for the severe-to-profoundly deaf.

CryoPlasty® Therapy may be an alternative to surgery or limb amputation

“We made progress on a number of fronts, most notably the integration of Guidant and our quality initiatives," said Jim Tobin, President and CEO.

FLEXView™ System enables physicians to perform less-invasive cardiac surgical ablation procedures

Company welcomes FDA statement that drug-eluting stents remain safe and effective when used for approved indications

NEJM editorial and articles describe results of two randomized clinical trials, PASSION and TYPHOON

Boston Scientific Corporation (NYSE: BSX) today announced four-year follow-up data from its TAXUS II paclitaxel-eluting stent system...

Initial six-month results show positive outcomes in diabetic patients; safety events for diabetic subset lower than overall patient population

International data suggests low revascularization rates for both TAXUS stent and PROMUS™ (XIENCE™ V) stent

PROMUS Stent joins market-leading TAXUS® Paclitaxel-Eluting Coronary Stent Systems

Results expected to continue to support safety and performance of Boston Scientific's second-generation drug-eluting stent system

Company also to host WCC symposia on drug-eluting stents, therapies in cardiac rhythm management and carotid artery disease

"The second quarter was a transforming one for Boston Scientific," said Jim Tobin, President and CEO

Precision™ SCS System, the first and smallest rechargeable system, achieves rapid adoption

Initial six-month results consistent with previous TAXUS registries

New system enhances diagnosis and treatment of blocked vessels and heart disorders

New Jaw Configuration Designed to Yield Larger Tissue Specimens and Improve Procedural Outcomes

Young will be responsible for all quality assurance and reliability functions for the CRM Group, including product performance reporting

A live webcast and replay of the Thursday, July 27 conference call will be available

Report analyzed data from nearly 23,000 U.S. patents and 9,000 U.S. patent applications

Company is providing safety information and retrieving a specific subset of pacemakers, cardiac resynchronization pacemakers and implantable cardioverter defibrillators

A live webcast and replay of the June 27 conference session will be available

Jury had found that J&J's Cypher® stent product infringed a Boston Scientific drug coating patent

Boston Scientific's TAXUS stent system used in more complex lesions than J&J's Cypher

A live webcast and replay of the June 13 conference session will be available

Company plans to use the net offering proceeds for general corporate purposes

Company expects to receive the offering proceeds upon closing on June 9, 2006

Technology features powerful combination of deliverability and trackability to enhance clinical versatility

Rio™ Aspiration Catheter is indicated for use in the removal of thrombi, or clots, from vessels throughout the body

In upholding the trial court, the Court of Appeals agreed that Boston Scientific's products were not within the scope of the Medtronic patents

Researchers say novel visualization capability may reduce common need for repeat procedures

Trial advances understanding of dual-chamber pacing for patients at risk of sudden cardiac death

LATITUDE® Patient Management System aligns closely with recent ACC/AHA guidelines on managing heart failure

Physician society draft recommendations reinforce LATITUDE Active Monitoring ™ capabilities

Physicians offer preview of SpyGlass™ Direct Visualization System

New second-generation training center in Brussels to help medical professionals advance standard of patient care

TAXUS benefits demonstrated in non-diabetic patient population carry over into insulin-treated diabetic patients

TAXUS VI results support positive safety and efficacy profile

Boston Scientific's second generation stent compares favorably to market leading TAXUS Express2™ stent system, even with more complex lesions

Company made the announcement at the annual Paris Course on Revascularization (EuroPCR).

Boston Scientific's second-generation stent system now approved for treatment of acute mycocardial infarction, total occlusions and in-stent restenosis

Cardiac Rhythm Management (CRM) Group is formerly Guidant's CRM business; Boston Scientific acquired Guidant on April 21

Court also upheld its earlier decision dismissing the TAXUS® Liberte™ product from the case, without prejudice

Pending approval from the Board of Directors, Dr. Baim will also join Boston Scientific's Executive Committee

Boston Scientific is the exclusive U.S. distributor of this product for a new treatment option for female stress urinary incontinence

Results to include nine-month data on TAXUS® Liberte™

Lawsuit alleges that the Conor CoStar™ Paclitaxel-Eluting Coronary Stent System infringes a balloon catheter patent owned by Boston Scientific

Court finds Sahajanand's Infinnium paclitaxel-eluting stent infringed two claims of an Angiotech patent

Endoscopic vessel harvesting speeds recovery and reduces pain and scarring; new products offer clinicians more choices to improve patient outcomes

A live webcast and replay of the May 4 conference session will be available

A live webcast and replay of the May 2 conference session will be available

Includes recommendations for the surveillance, analysis and performance reporting of pacemakers and implantable cardioverter defibrillators (ICDs)

Both were members of the board of directors of Guidant Corporation, which was acquired by the Company last week

Company elected to adjust the interest rates due to the closing of the Company's acquisition of Guidant Corporation

Creates a global leader in cardiovascular devices and one of the largest medical technology companies in the world

Transaction scheduled to close tomorrow

"We are very pleased that we achieved record company sales for the quarter," said Jim Tobin, President and Chief Executive Officer

New study seeks to define potential of Precision™ system to treat large population of U.S. migraine sufferers who don't respond adequately to current therapies

Company must also receive antitrust approval from the U.S. Federal Trade Commission (FTC) before it can close the Guidant transaction

A live webcast and replay of the April 18 conference call will be available

Agreement subject to approval by FTC Commissioners

Company's newest addition to its broad portfolio of vascular access products

At separate special meetings today, shareholders of each company have voted overwhelmingly to approve

Features a number of elements designed to enhance steering, handling and tracking during peripheral and coronary procedures

Diabetics and other complex patients see strong results with TAXUS stents

Company plans to appeal the judgment of the Delaware U.S. District Court

Details currently confidential; will become public when the European Commission announces its decision

ISS report notes the "compelling strategic rationale" for the combination of companies

Results of the study were published in today's edition of JAMA

Six-month results are consistent with ARRIVE I data

Complex insulin-treated diabetic population shows numerical trend toward improved MACE outcomes with TAXUS versus Cypher

TAXUS trials continue to deliver positive outcomes in complex cases

Team will lead CRM Group following acquisition of Guidant

Completes Company's application for FDA approval

Results highlight efficacy of TAXUS in most complex lesions and highest risk patients

A live webcast and replay of the March 9 conference session will be available

Shareholders of both companies to vote on March 31, 2006

A live webcast and replay of the March 7 conference session will be available

(February 15, 2006) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received reimbursement approval from the French government for its TAXUS

"We reviewed with the FDA a path to resolve the issues they have identified, and we committed to working closely with them to ensure they are resolved," said Tobin

A live webcast and replay of the February 8 conference session will be available

A live webcast and replay of the February 7 conference call will be available